NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

NCT03344094

CompletedN/A

Sponsor: University of Chicago

Conditions: Multiple Sclerosis, Immune System Diseases

Interventions: ocrelizumab

Countries: United States

Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All patients who are eligible for Ocrelizumab therapy based on FDA criteria

Exclusion Criteria:

* All patients who are ineligible for Ocrelizumab therapy based on FDA criteria.
* Prior treatment with Alemtuzumab or stem cell therapy, or immune abnormalities that would interfere with planned tests.
* Hepatitis B and HIV infections.
* Pregnant or lactating women.
* Hypersensitivity to trial medications.

Locations (1)

Chicago, Illinois, United States